Artificial intelligence for drug discovery.
Atomwise is a preclinical tech-enabled biotech using machine learning for hit discovery, hit expansion, and lead optimization. We were the first team to apply convolutional neural networks to drug discovery. We focus on identifying and optimizing novel small molecule scaffolds and unlocking previously-undrugged protein targets.
Active Founders
Abraham Heifets, CEO
Abraham Heifets is cofounder and CEO of Atomwise. He was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched compilers for high-performance data processing at IBM's T.J. Watson Research Center and helped build the AI system of the world-champion robotic soccer team at Cornell University. He was Time's Person of the Year in 2006.
Izhar Wallach, CTO
